πŸ‡ΊπŸ‡Έ

US SEC Filing Intelligence

Β· daily

New Federal Contractors β€” March 27, 2026

This one-day snapshot reveals $1.25B in new federal contract obligations, dominated by bullish IT/services (49%) and construction/infrastructure (38%) awards, signaling robust demand amid fiscal year-end reporting. Leidos captures $146M across two long-term IT deals (IRS/FAA), while ThunderCat's $222M VA IT order offers $1.56B ceiling potential. Sustained multi-year commitments through 2037 underscore revenue visibility for select contractors, though firm-fixed-price structures flag margin risks on 80% of value.

10 total filings
Β· daily

Significant Contract Modifications ($10M+) β€” March 27, 2026

This single-day stream of 10 significant contract modifications (> $10M) totals $1.25B in obligations, with 8 bullish signals dominated by IT/services and construction sectors, signaling robust federal spending continuity. Leidos stands out with $146M across two awards, bolstering long-term revenue visibility through 2037. Firm fixed price structures prevalent (80% of contracts) introduce execution risks, but high outlays in several (e.g., 60-99%) indicate strong funding momentum.

10 total filings
Β· daily

Contract Deobligations Alert β€” March 27, 2026

This Contract Deobligations Alert reveals $1.25B in large federal obligations, predominantly bullish (8/10) signals for IT services, construction, and health providers, with multi-year revenue visibility through 2037 for select firms. Leidos (LDOS) captures $146M across IRS and FAA IT/aero contracts, while Tutor Perini (TPC) and General Dynamics (GD) secure infrastructure and cyber wins amid firm-fixed-price dominance. Risks from low outlays ($0 in 3 contracts) and cost overrun exposure warrant monitoring, but option exercises could unlock $2B+ upside.

10 total filings
Β· daily

Contract Option Exercises β€” March 27, 2026

This single-day snapshot of $1.25B in federal contract option exercises signals strong revenue visibility for IT/services and construction firms, with 8/10 bullish awards totaling over $1.1B obligated. Leidos captures $146M across IRS/FAA IT deals (90%+ outlayed on one), while ThunderCat's $222M VA IT order (with $1.56B options) highlights massive upside in veteran-owned IT. Firm fixed price dominance (9/10) flags margin risks amid low outlays on several large awards.

10 total filings
Β· daily

Federal Professional Services Contracts β€” March 27, 2026

A single massive $124.8M CMS delivery order to Empower AI signals strong federal demand for administrative management consulting in healthcare, with over 60% ($75M) already outlayed securing multi-year revenue through 2027. This bullish award via full competition underscores Empower AI's competitive edge in NAICS 541611 services. Investors should monitor execution of the remaining $49.7M obligation under firm fixed price terms amid subaward dependencies.

1 total filings
Β· daily

Federal IT & Cybersecurity Contracts β€” March 27, 2026

Federal IT & cybersecurity contracts show $379M obligated value across VA, DOT, and Treasury, with $2.33B in potential base+options signaling multi-year revenue upside for winners. ThunderCat and Leidos drive bullish signals via high obligations/outlays and SDVOSB/competitive strengths, while GDIT's legacy FAA contract lags with $0 outlay despite $81M obligation. Firm fixed-price structures dominate, amplifying execution risks but highlighting sector demand stability through 2030.

3 total filings
Β· daily

All HHS Contracts β€” March 27, 2026

HHS issued $213.7M in long-term contracts (to 2027-2028) for CMS administrative consulting and BARDA biological R&D, with Empower AI showing bullish execution (60% of $125M outlayed) versus ATCC's neutral early-stage 5% progress on $89M. Corporate contractors gain revenue visibility amid health program support, but firm fixed-price and cost-plus structures expose remaining obligations to execution risks. Investors should prioritize Empower AI for near-term cash flow stability while monitoring HHS R&D funding continuity.

2 total filings
Β· daily

Mega Contracts Monitor ($100M+) β€” March 27, 2026

Six mega contracts totaling $934.3M across IT services, construction, and healthcare signal strong federal demand, providing revenue visibility for winners through 2027-2030. Construction/infrastructure awards dominate at ~50% ($472M), followed by IT/consulting (~37%, $347M) and health services (~12%, $115M), all under firm-fixed-price terms won via full/open competition. Bullish for listed firms, but monitor FFP execution risks and low outlays on three contracts ($0 disbursed despite $400M+ obligated).

6 total filings
Β· daily

High-Value Federal Grants ($5M+) β€” March 27, 2026

This week's $1.25B in high-value federal grants signals strong bullish momentum for IT/services and construction firms, with 8/10 awards bullish and Leidos securing $146M across IRS/FAA IT support through 2037. Long-term contracts (many to 2027+) provide revenue visibility amid firm fixed price dominance, though low outlays in 4 awards ($0 in 3) flag near-term cash flow risks. Institutional investors should prioritize Leidos and SDVOSB plays like ThunderCat for outsized federal exposure.

10 total filings
Β· daily

General Federal Contracts β€” March 27, 2026

Federal contracts totaling $1.25B highlight robust demand for IT services, construction, and health support, with 8 bullish signals dominated by firm fixed-price awards to firms like ThunderCat ($222M obligated, $1.56B ceiling) and Leidos (two awards totaling $146M). Long-term commitments through 2037 provide revenue visibility amid infrastructure and cyber priorities, though firm fixed-price structures pose execution risks. Investors should prioritize public equities like Leidos (LDOS) and General Dynamics (GD) for near-term upside from high outlays and option potential.

10 total filings
Β· daily

S&P 500 Technology Sector SEC Filings β€” March 27, 2026

Across 25 SEC filings in the USA S&P 500 Technology stream (despite diverse sectors), proxy season dominates with 12+ DEF 14A/DEFA14A filings for May 2026 annual meetings (AMD May 13, Murphy Oil May 13, CBU May 20, TSQ May 11, CPT), highlighting governance, comp approvals, and equity plans amid mixed financial trends. Period-over-period data shows growth outliers like Community Financial System's 9.7% YoY revenue increase (+$72.1M), 15.4% diluted EPS growth, and Murphy Oil's 3% production rise to 182 MBOEPD with 20% LOE/BOE reduction, contrasted by declines such as Muzinich BDC's 28% YoY investment income drop to $17.1M and AIM ImmunoTech's $82k revenue decrease with halted sales. Tech-specific signals include AMD's proposed +65M share equity plan, Planet Labs' full warrant redemption reducing dilution, and BlockchAIn Digital Infrastructure's $500M+ AI data center LOIs. Capital allocation trends favor shareholder returns (Murphy $286M, CBU 2.2% dividend hike for 33rd year), with auditor changes routine (Sun Communities, Portsmouth Square). No clustered insider trading, but forward-looking catalysts like AIB's webinar and exec transitions (SBA retirement Dec 2026) point to monitoring AI infra demand and governance votes. Portfolio implications: Selective bullishness in growth proxies/AI, caution on income declines/supply risks.

14 high priority 11 medium 25 total filings
Β· daily

Nasdaq 100 Stocks SEC Filings β€” March 27, 2026

Across 32 filings from NASDAQ-100 constituents and related names, proxy season dominates with 15+ DEF/DEFA14A filings announcing May 2026 annual meetings, signaling routine governance but highlighting dividend growth (e.g., PepsiCo's 54th consecutive increase) and board refreshes. Period-over-period trends show mixed financial health: bullish growth in select names like Murphy Oil (production +3% YoY to 182 MBOEPD, LOE/BOE -20% to $10.89) and Community Financial System (revenues +9.7% YoY, EPS +15.4%), contrasted by widening losses in TMC the metals (-150% YoY Q4 net loss to $40.4M) and Muzinich BDC (investment income -28% YoY). Capital allocation leans shareholder-friendly with PepsiCo and Community boosting dividends, while operational risks persist in biotech (AIM ImmunoTech halted sales) and metals (TMC permitting delays). Vanguard's 13G/A amendments across Netflix, MSFT, PYPL, TSLA, WMG reflect passive realignments with no ownership shifts, maintaining stability in mega-caps. Portfolio-level, energy/financials outperform (avg +10% YoY metrics) vs metals/biotech underperformance (-20% avg), with May meetings as key catalysts for compensation votes and auditor ratifications. Implications: Favor dividend growers amid volatility, monitor biotech/metal turnarounds.

17 high priority 15 medium 32 total filings
Β· daily

S&P 500 Financials Sector SEC Filings β€” March 27, 2026

Across 50 diverse SEC filings from the USA S&P 500 Financials intelligence stream (including banks, REITs, insurers alongside adjacent sectors), key themes include heightened M&A and restructuring activity (e.g., mergers at Two Harbors, Dillard's, Allegiant), routine proxy season launches with neutral sentiment, and mixed financial results showing revenue growth in 12/50 filings (avg +25% YoY where reported, e.g., Worthington +24%, Legence +34.6% Q4) but widening losses in biotechs/miners (e.g., TMC FY loss +290% YoY to $320M). Period-over-period trends reveal organic sales expansion (Worthington +14%) offset by margin compression (Worthington gross margin -40 bps, Legence Q4 -60 bps) and credit deterioration in financials (Avidia Bancorp charge-offs $21M, nonaccruals +406% YoY). Forward-looking catalysts cluster in H1 2026: spin-offs (AnaptysBio Apr 20), AGMs (May cluster), compliance plans (BiomX Apr 24), and raised guidances (Legence FY26 rev $3.7-3.9B, +42% midpoint YoY). Capital allocation leans shareholder-friendly with buybacks (Carnival $2.5B), dividends (Blue Owl monthly $0.0748/share), and refinancings (Delek Logistics new credit facility), but no broad insider trading patterns emerge. Portfolio implications: overweight M&A targets for near-term premiums, monitor bank credit risks amid NIM expansion (Avidia +40 bps to 3.29%), and favor revenue growers with liquidity buffers (Kailera $546M cash/secs). Overall sentiment mixed/neutral (32/50), with 10/50 positive on growth catalysts.

27 high priority 23 medium 50 total filings
Β· daily

S&P 500 Consumer Staples Sector SEC Filings β€” March 27, 2026

Across 50 diverse SEC filings (primarily proxies, 8-Ks, and 10-Ks, with limited true S&P 500 Consumer Staples representation like PEP, HAIN, MNST), proxy season dominates with 10+ annual/virtual meetings clustered in May 2026 (e.g., PEP May 6, F May 14, MNST May 14), signaling routine governance but opportunities in dividend votes and board refreshes. Period-over-period trends reveal revenue growth in outliers (Aurora Mobile +19% YoY to RMB 375M, MicroCloud +39% YoY to RMB 404M, Lifeloc +6% to $9M) but widespread declines in commodity funds (US Oil Fund assets -25.8% YoY to $37M, US NatGas -1.2% to $19M) and product revenues (Kopin -42% YoY to $8.4M); margins stable/flat in Lifeloc (40.3%) but implied compression in MicroCloud (~21% from 23%). Capital allocation highlights PEP's 54th consecutive dividend hike (June 2026 payment); forward-looking catalysts include drug sNDAs (BioXcel YE2026), Phase 3 readouts (Kodiak), and M&A (Clear Channel merger post-go-shop). Risks cluster around listing deficiencies (HAIN, Alight < $1 bids) and cyber incidents (CareCloud); portfolio-level theme: resilient servicing in 12+ Exeter ABS trusts but sector mismatches dilute staples focus, implying broader market stability amid energy/biotech volatility.

31 high priority 19 medium 50 total filings
Β· daily

S&P 500 Industrials Sector SEC Filings β€” March 27, 2026

Across 50 filings from S&P 500 Industrials and related sectors, proxy statements dominate (e.g., DEF 14A/DEFA14A for Marriott, Murphy Oil, Aspen Aerogels, 3M, Norfolk Southern, Ampco-Pittsburgh, Camden), signaling routine governance with neutral sentiment but highlighting board changes and upcoming AGMs in May 2026. Financial results show mixed trends: strong revenue growth in industrials like Legence (+21.5% FY2025 to $2.6B, +34.6% Q4) contrasts with declines in tech-adjacent like Luminar (-12% YoY revenue to $66M), Phunware (-19.9% to $2.6M), and Ideal Power (-56% to $38k), while banks/financials like Avidia report net losses from credit deterioration (nonaccruals +406% YoY to $20M). M&A activity is bullish with Great Lakes Dredge tender at $17/share, Bank of Nagoya MOU for 2028 integration (synergies in assets Β₯22T combined), and tuck-ins like Legence's Bowers Group. Capital returns strong at Banco Santander (EUR 3.5B dividends, share cancellations) and Murphy Oil ($286M free cash flow returned). Forward guidance positive for Legence (FY2026 rev $3.7-3.9B, up from prior), Aspen (Q1 2026 $38M settlement, 2027-2028 contracts), but risks from legal overhangs in student loan trusts and NYSE delisting warning for Alight. Portfolio-level: Industrials show resilient backlog growth (Legence +49% to $3.7B) amid margin pressures (Q4 gross margin -60bps to 20%), with catalysts clustered in May AGMs.

34 high priority 16 medium 50 total filings
Β· daily

S&P 500 Energy Sector SEC Filings β€” March 27, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, proxy statements dominate (4/7 filings for Ampco Pittsburgh and EOG Resources), signaling the start of 2026 proxy season with neutral sentiment and unanimous board recommendations FOR director elections, say-on-pay votes, and auditor ratifications at AGMs on May 8 (Ampco) and May 20 (EOG). Knightscope's FY2025 10-K provides the only substantive financials, revealing 5% YoY revenue growth to $11.3M (services +7% to $8.0M, products +1% to $3.4M) but sharply deteriorating gross margins to -42% from -34% (-800bps), operating loss expansion to $33.9M driven by 77% R&D surge to $12.5M, and net loss to $33.8M (+6.5% YoY), offset by cash build to $20.6M via $42.2M financing (+22% YoY). Hallador Energy reported a contestable MSHA imminent danger order at Oaktown Mine with no injuries or production halt (mixed sentiment), while Stoke Therapeutics completed a clean auditor switch to EY for FY2026 (neutral). No insider trading, M&A, or capital allocation details emerged; forward-looking focuses on 2026 auditors and AGMs. Sector themes include governance routine amid isolated profitability erosion and regulatory watch items, implying neutral portfolio positioning with low materiality (avg 6.4/10) but actionable AGM catalysts.

3 high priority 4 medium 7 total filings
Β· daily

US Material Events SEC 8-K Filings β€” March 27, 2026

Across the 50 US SEC filings from March 27, 2026, the dominant themes are widespread executive and board transitions (observed in 25+ filings, including 10+ CEO/CFO changes and 15+ director resignations/appointments), robust financing and refinancing activities (16 instances, including $1.5B+ facilities and $500M+ debt/equity raises), and select M&A/spin-off developments amid neutral-to-positive sentiment (avg materiality 7/10). No explicit aggregate YoY/QoQ financial trends are detailed, but implied liquidity enhancements via new credit lines (e.g., Delek, Enterprise, News Corp) and equity facilities (Cyber Enviro-Tech $30M, LM Funding $75M) signal proactive capital allocation for growth/reinvestment over dividends/buybacks. Critical developments include AnaptysBio's value-unlocking spin-off (April 20 distribution), Two Harbors' $10.80/share merger (H2 2026 close), and Iterum Therapeutics' liquidation petition (hearing April 13)β€”flagging biotech distress vs. sector resilience. Portfolio-level patterns show shipping/energy firms focusing on debt refinancing (positive for stability), SPACs/biotechs with leadership churn (mixed conviction), and cruise/retail with activist-driven board refreshes (Norwegian Cruise). Market implications: heightened M&A catalysts, monitor leadership stability for conviction signals, and favor liquidity-strong names amid potential volatility from transitions.

50 high priority 50 total filings
Β· daily

Dow Jones 30 Stocks SEC Filings β€” March 27, 2026

Across the 50 filings for USA Dow Jones 30 constituents and related entities, M&A activity dominates with 10+ deals including Two Harbors' $10.80/share cash merger with CrossCountry Mortgage (closing H2 2026), Allegiant Travel's stock+cash acquisition of Sun Country (pro forma 2025 revenues $3.7B), and multiple JFB Construction/XTEND drone mergers highlighting defense synergies. Period-over-period trends show stark bifurcation: explosive revenue growth in digital assets (BitGo +424% YoY to $16.2B) and select financials (Indivior +4% to $1.24B, Adjusted EBITDA +20%), contrasted by declines in industrials/tech (Kopin Q4 revenues -42% YoY, SpringBig FY2025 -7.4%, SBC Medical FY2025 -15%). Positive clinical and defense catalysts (Kodiak Sciences Phase 3 success, XTEND $500M pipeline/$71M backlog) offset proxy-heavy neutral sentiment, with capital allocation favoring buybacks (Indivior $400M authorization) and financings ($30M CETI equity line, $56M Kopin placement). Portfolio-level margin trends mixed (Indivior +500bps to 35%, SBC -3pts to 40%), but overall bullish M&A wave implies sector consolidation; watch H2 2026 closings for blue-chip upside amid volatile growth patterns.

28 high priority 22 medium 50 total filings
Β· daily

US SEC Filings Daily Market Digest β€” March 27, 2026

The March 27, 2026, SEC filings digest reveals a dominant proxy season theme with 15+ DEFA14A/DEF 14A filings for May 2026 AGMs across sectors like airlines (Southwest, Murphy Oil), pharma (Indivior, Nurix), and metals (Trilogy), signaling routine governance but highlighting positive 2025 recaps (e.g., Indivior revenue +4% YoY to $1.24B, Murphy Oil production +3% YoY to 182 MBOEPD). 10-Ks show stark mixed performance: revenue growth in Sportradar (+17% YoY to €1.29B), BitGo (+424% to $16.2B), but declines in Luminar (-12% YoY to $66M), Phunware (-20% YoY to $2.6M), and SpringBig (-7% YoY to $22.8M), with margin expansions in Indivior (+500 bps to 35%) offset by compressions elsewhere. Biotech shines with Kodiak's Phase 3 GLOW2 success and Nurix's 83% ORR, while credit funds (Oaktree, Blue Owl) maintain stable leverage (0.57x-0.82x) and distributions ($0.0748/share monthly). SPACs/blank checks (BHAV, AltEnergy) report IPOs and leadership changes, and capital allocation favors returns (Indivior $400M buyback, News Corp $1B repurchase). Overall, portfolio trends indicate resilient credit/income strategies amid tech/autonomy weakness, with May AGMs as key catalysts for comp votes and auditor ratifications.

28 high priority 22 medium 50 total filings
Β· daily

S&P 500 Consumer Discretionary Sector SEC Filings β€” March 27, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with outliers in energy/commodities, infra, and finance), proxy season dominates with 15+ DEF/DEFA14A filings signaling May 2026 AGMs for firms like Marriott, Ford, Equifax, and Haverty, focusing on director elections, comp approvals, and governance amid mixed 2025 results. Period-over-period trends show modest revenue growth in retail/furniture (Haverty +5% YoY sales, Lifeloc +6%), but sharp declines in commodity funds (oil/gas ETFs assets down avg 20% YoY, e.g., US 12 Month Oil -25.8%), widening losses in graphite/mining (GrafTech net loss to $219.8M from $131.2M), and narrowing losses in biotech (Werewolf -14% YoY). M&A activity surges with 8 deals/tenders (Great Lakes $17/share tender, JFB/XTEND $1.5B combo with $71M backlog/$500M pipeline, Shizuoka-Nagoya integration), signaling consolidation for synergies. Capital allocation leans conservative (dividends up at Community Financial 33rd year +2.2%, LM Funding >3.3M shares repurchased), with strong balance sheets (Haverty zero debt/$125M cash). Forward-looking catalysts cluster in mid-2026 M&A closings and Q1 2026 production ramps (Lifeloc SpinDetect), but risks from cash burn (Werewolf runway to Q4 2026) and covenant relaxations (OFS min NII cut to $1M). Overall, defensive retail outperforms volatile commodities, favoring M&A plays over pure consumer exposure amid cautious spending.

25 high priority 25 medium 50 total filings